<--GAT-->

FDA Approves Option for Schizophrenia, Bipolar Treatment

by U.S. Medicine

October 11, 2015

JERSEY CITY, NJ – A new option for treating schizophrenia and bipolar disorder in adults has been approved by the Food and Drug Administration.

The drug Vraylar, cariprazine in capsule form, is manufactured by Forest Laboratories LLC of Jersey City, NJ, and distributed by Actavis Pharma Inc. of Parsippany, NJ.

“Schizophrenia and bipolar disorder can be disabling and can greatly interfere with day-to-day activities,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “It is important to have a variety of treatment options available to patients with mental illnesses so that treatment plans can be tailored to meet a patient’s individual needs.”

In each of three six-week clinical trials involving 1,754 participants, Vraylar was shown to reduce the symptoms of schizophrenia compared to placebo, according to the FDA. In addition, the drug’s effectiveness in treating bipolar disorder was shown in a trio of three-week clinical trials of 1,037 participants.

The FDA notes that Vraylar and all other FDA-approved drugs used to treat schizophrenia and bipolar disorder have a Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs in older people with dementia-related psychosis, adding that neither Vraylar nor any other drug in this class is approved to treat such patients.


Comments are closed here.


Related Articles

After 40 Years, VA Study Finds Antipsychotics No Help for Delirium

For more than 40 years, haloperidol and ziprasidone have been given to critically ill patients who develop delirium in hospital intensive care units.

Program Helps Reduce Domestic Violence Involving Returning Servicemembers

While intimate partner violence in the military population has been found to occur at about the same rate as the civilian population, servicemembers and veterans face unique challenges: a lack of separation between home and work life, long separations from family and repeated exposure to combat and other traumatic situations.


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

Long-Acting Insulins Approved by FDA

WASHINGTON—Recent problems with initiatives implemented by the Veterans Benefits Administration point to much larger, systemic issues in how the agency rolls out new programs, according to the VA Office of the Inspector General. Appearing before... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

WASHINGTON—Recent problems with initiatives implemented by the Veterans Benefits Administration point to much larger, systemic issues in how the agency rolls out new programs, according to the VA Office of the Inspector General. Appearing before... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

WASHINGTON—Recent problems with initiatives implemented by the Veterans Benefits Administration point to much larger, systemic issues in how the agency rolls out new programs, according to the VA Office of the Inspector General. Appearing before... View Article

FDA News

Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies

WASHINGTON—Recent problems with initiatives implemented by the Veterans Benefits Administration point to much larger, systemic issues in how the agency rolls out new programs, according to the VA Office of the Inspector General. Appearing before... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up